The prognostic value of late gadolinium enhancement CMR in nonischemic cardiomyopathies topical collection on cardiac PET, CT, and MRI

Current Cardiology Reports

Volumn 15, Issue 1, 2013, Pages

  Karamitsos, Theodoros D ^a   Neubauer, Stefan ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular magnetic resonance; CMR; Fibrosis; Late gadolinium enhancement; Nonischemic cardiomyopathies; Outcome; Prognosis

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM; DIAGNOSTIC AGENT;

ANATOMICAL VARIATION; AORTA STENOSIS; ARRYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART HEMOSIDEROSIS; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IRON OVERLOAD; ISCHEMIC HEART DISEASE; LATE GADOLINIUM ENHANCEMENT TECHNIQUE; MYOCARDITIS; NONISCHEMIC CARDIOMYOPATHY; PROGNOSIS; PULMONARY HYPERTENSION; RISK ASSESSMENT; SARCOIDOSIS; CARDIOMYOPATHY; FIBROSIS; HEART MUSCLE; IMAGE ENHANCEMENT; MAGNETIC RESONANCE ANGIOGRAPHY; METHODOLOGY; PATHOLOGY; REVIEW;

CARDIOMYOPATHIES; CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE ANGIOGRAPHY; MYOCARDIUM; PROGNOSIS;

EID: 84872778197     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0326-2     Document Type: Article

References (64)

1. Pohost GM. The history of cardiovascular magnetic resonance. JACC Cardiovasc Imaging. 2008;1:672-8.
2. Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009;54:1407-24.
3. Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial gd-dtpa kinetics determine mri contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94:3318-26. (Pubitemid 26427504)
4. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of mri delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2002. (Pubitemid 29529292)
5. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, et al. Contrast-enhanced mri and routine single photon emission computed tomography (spect) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003;361:374-9. (Pubitemid 36164969)
6. •• Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-53. Landmark study which established the use of late gadolinium enhancement to predict regional function post revascularization.
7. Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, Petersen SE, Taggart DP, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation. 2004;110:1535-41. (Pubitemid 39297973)
8. • Pegg TJ, Selvanayagam JB, Jennifer J, Francis JM, Karamitsos TD, Dall'Armellina E, et al. Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:56. An important paper which describes the ability of late gadolinium enhancement to predict not only regional but also global recovery of function post revascularization.
9. Cheong BY, Muthupillai R, Wilson JM, Sung A, Huber S, Amin S, et al. Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction. Circulation. 2009;120:2069-76.
10. Kwon DH, Halley CM, Carrigan TP, Zysek V, Popovic ZB, Setser R, et al. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc Imaging. 2009;2:34-44.
11. Kwong RY, Chan AK, Brown KA, Chan CW, Reynolds HG, Tsang S, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 2006;113:2733-43. (Pubitemid 43947991)
12. Kwong RY, Sattar H, Wu H, Vorobiof G, Gandla V, Steel K, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation. 2008;118:1011-20.
13. Rahimi K, Banning AP, Cheng AS, Pegg TJ, Karamitsos TD, Channon KM, et al. Prognostic value of coronary revascularisation-related myocardial injury: a cardiac magnetic resonance imaging study. Heart. 2009;95:1937-43.
14. Schmidt A, Azevedo CF, Cheng A, Gupta SN, Bluemke DA, Foo TK, et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation. 2007;115:2006-14. (Pubitemid 46625951)
15. Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM, et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114:32-9. (Pubitemid 44305272)
16. Karamitsos TD, Francis JM, Neubauer S. The current and emerging role of cardiovascular magnetic resonance in the diagnosis of nonischemic cardiomyopathies. Prog Cardiovasc Dis. 2011;54:253-65.
17. Lehrke S, Lossnitzer D, Schob M, Steen H, Merten C, Kemmling H, et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart. 2011;97:727-32.
18. McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54-9. (Pubitemid 36859020)
19. •• Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977-85. An important paper which describes the prognostic value of midwall fibrosis in patients with dilated cardiomyopathy. (Pubitemid 44738448)
20. Nazarian S, Bluemke DA, Lardo AC, Zviman MM, Watkins SP, Dickfeld TL, et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 2005;112:2821-5. (Pubitemid 41641676)
21. Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:2414-21. (Pubitemid 351826874)
22. Iles L, Pfluger H, Lefkovits L, Butler MJ, Kistler PM, Kaye DM, et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2011;57:821-8.
23. Leong DP, Chakrabarty A, Shipp N, Molaee P, Madsen PL, Joerg L, et al. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. Eur Heart J. 2012;33:640-8.
24. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14:13.
25. Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol. 2009;53:284-91.
26. Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008;1:184-91.
27. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369-74. (Pubitemid 351443083)
28. Kwon DH, Setser RM, Popovic ZB, Thamilarasan M, Sola S, Schoenhagen P, et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced mri study. Int J Cardiovasc Imaging. 2008;24:617-25.
29. • O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867-74. A study that assessed the prognostic value of late gadolinium enhancement in patients with hypertrophic cardiomyopathy.
30. • Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:875-87. A study that assessed the prognostic value of late gadolinium enhancement in patients with hypertrophic cardiomyopathy.
31. Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3:51-8. A study that assessed the prognostic value of late gadolinium enhancement in patients with hypertrophic cardiomyopathy.
32. Appelbaum E, Maron BJ, Adabag S, Hauser TH, Lesser JR, Haas TS, et al. Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2012;5:78-85.
33. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533-41.
34. Hunold P, Wieneke H, Bruder O, Krueger U, Schlosser T, Erbel R, et al. Late enhancement: a new feature in mri of arrhythmogenic right ventricular cardiomyopathy? J Cardiovasc Magn Reson. 2005;7:649-55. (Pubitemid 41176830)
35. Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, Nasir K, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005;45:98-103. (Pubitemid 40052034)
36. Karamitsos TD, Neubauer S. Cardiovascular magnetic resonance in heart failure. Curr Cardiol Rep. 2011;13:210-9.
37. Childs H, Friedrich MG. Cardiovascular magnetic resonance imaging in myocarditis. Prog Cardiovasc Dis. 2011;54:266-75.
38. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a jacc white paper. J Am Coll Cardiol. 2009;53:1475-87.
39. •• Grun S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol. 2012;59:1604-15. This study assessed the prognostic value of late gadolinium enhancement in patients with myocarditis.
40. • Austin BA, Tang WH, Rodriguez ER, Tan C, Flamm SD, Taylor DO, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2009;2:1369-77. This study assessed the prognostic value of late gadolinium enhancement in patients with amyloidosis.
41. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186-93. (Pubitemid 40139730)
42. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3:155-64.
43. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008;51:1022-30. (Pubitemid 351318125)
44. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008;10:54.
45. Patel AR, Klein MR, Chandra S, Spencer KT, Decara JM, Lang RM, et al. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail. 2011;13(11):1231-7. doi: 10.1093/eurjhf/hfr099.
46. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969-77.
47. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683-90. (Pubitemid 40704507)
48. Karamitsos TD, Myerson SG. The role of cardiovascular magnetic resonance in the evaluation of valve disease. Prog Cardiovasc Dis. 2011;54:276-86.
49. • Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina G, et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol. 2011;58:1271-9. This study assessed the prognostic value of late gadolinium enhancement in patients with aortic stenosis.
50. Blyth KG, Groenning BA, Martin TN, Foster JE, Mark PB, Dargie HJ, et al. Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J. 2005;26:1993-9. (Pubitemid 41435724)
51. Shehata ML, Lossnitzer D, Skrok J, Boyce D, Lechtzin N, Mathai SC, et al. Myocardial delayed enhancement in pulmonary hypertension: pulmonary hemodynamics, right ventricular function, and remodeling. AJR Am J Roentgenol. 2011;196:87-94.
52. Freed BH, Gomberg-Maitland M, Chandra S, Mor-Avi V, Rich S, Archer SL, et al. Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2012;14:11.
53. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the uk and relation to t2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
54. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac t2*magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961-8.
55. Kirk P, Carpenter JP, Tanner MA, Pennell DJ. Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2011;13:8.
56. • White SK, Sado DM, Flett AS, Moon JC. Characterising the myocardial interstitial space: the clinical relevance of non-invasive imaging. Heart. 2012;98:773-9. Interesting review article which summarizes the role of CMR and other imaging modalities in the characterisation of myocardial interstitial space.
57. Piechnik SK, Ferreira VM, Dall'armellina E, Cochlin LE, Greiser A, Neubauer S, et al. Shortened modified look-locker inversion recovery (shmolli) for clinical myocardial t1-mapping at 1.5 and 3 t within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010;12:69.
58. Dall'Armellina E, Piechnik SK, Ferreira VM, Si QL, Robson MD, Francis JM, et al. Cardiovascular magnetic resonance by non contrast t1-mapping allows assessment of severity of injury in acute myocardial infarction. J Cardiovasc Magn Reson. 2012;14:15.
59. Messroghli DR, Walters K, Plein S, Sparrow P, Friedrich MG, Ridgway JP, et al. Myocardial t1 mapping: application to patients with acute and chronic myocardial infarction. Magn Reson Med. 2007;58:34-40. (Pubitemid 47229915)
60. Ferreira VM, Piechnik SK, Dall'Armellina E, Karamitsos TD, Francis JM, Choudhury RP, et al. Non-contrast t1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to t2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:42.
61. •• Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122:138-44. One of the first studies showing the ability of CMR to assess diffuse fibrosis in hypertrophic cardiomyopathy and aortic stenosis.
62. Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M. Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. Circ-Cardiovasc Imaging. 2010;3:727-34.
63. • Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, et al. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008;295:H1234-42. One of the first studies showing the ability of CMR to assess diffuse fibrosis in patients with dilated cardiomyopathy.
64. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced t1 mapping. J Am Coll Cardiol. 2008;52:1574-80.